
Avantor Inc. (AVTR) Stock Forecast & Price Target
Avantor Inc. (AVTR) Analyst Ratings
Bulls say
Avantor Inc. is positioned positively due to significant market share gains of $100 million resulting from successful contract renegotiations, which are expected to enhance volume and lead to better fixed cost absorption. The company operates in a robust healthcare sector and anticipates margin expansion that aligns more closely with industry peers, suggesting potential for multiple expansion over time. Furthermore, ongoing demand for Avantor's core mAb platform and projected cost savings exceeding $250 million by 2025 underscore a solid foundation for future growth.
Bears say
Avantor Inc. has revised its FY25 organic revenue growth outlook downward to between -2% and 0%, reflecting persistent headwinds in the bioprocessing sector and a revenue decline in 2Q. The company anticipates a further contraction in organic growth for 3Q25, with projections of -4% to -2%, amidst challenges faced by key bioprocess customers and inventory adjustments in the silicone materials segment. Additionally, the adjusted EBITDA margins missed consensus expectations, and the overall financial performance indicates a sustained vulnerability, which could hinder any potential recovery in the near term.
This aggregate rating is based on analysts' research of Avantor Inc. and is not a guaranteed prediction by Public.com or investment advice.
Avantor Inc. (AVTR) Analyst Forecast & Price Prediction
Start investing in Avantor Inc. (AVTR)
Order type
Buy in
Order amount
Est. shares
0 shares